[Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].

Abstract

The efficacy of systemic chemotherapy (CDDP + IFO + 5-FU or CDDP + IFO + CPT-11) was evaluated in 41 patients with malignant pleural effusion secondary to adenocarcinoma of the lung. The overall response rate for measurable disease was 56.1%. The response for pleural effusion was evaluated according to the criteria of the Japan Lung Cancer Society. The overall response for pleural effusion was 53.7% (34.1% CR and 19.5% PR). The median survival time was 361 days. These results suggested that systemic chemotherapy is an effective treatment for pleuritis carcinomatosa.

• Authors: A Fujita, H Takabatake, S Tagaki, K Sekine
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 24 Issue 13 Pg. 1987-91 (Oct 1997) ISSN: 0385-0684 [Print] Japan
• PMID: 9350247 (Publication Type: Journal Article)

Chemical References

• Granulocyte Colony-Stimulating Factor
• Irinotecan
• Cisplatin
• Fluorouracil
• Ifosfamide
• Camptothecin

Topics

• Adenocarcinoma (drug therapy, mortality)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Camptothecin (administration & dosage, analogs & derivatives)
• Cisplatin (administration & dosage)
• Drug Administration Schedule
• Female
• Fluorouracil (administration & dosage)
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Humans
• Ifosfamide (administration & dosage)
• Irinotecan
• Lung Neoplasms (drug therapy, mortality)
• Male
• Middle Aged
• Pleural Effusion, Malignant (drug therapy, etiology)
• Pleurisy (drug therapy, etiology)
• Retrospective Studies
• Survival Rate